drugset
drugset / Trial / NCT06054789

Clinical Study on 68Ga-PSMA-33 for PET/CT Imaging of Prostate Cancer

NCT06054789 ↗

Unknown 8 enrolled Nanjing First Hospital, Nanjing Medical University
NaSingle-groupOpen-labelDiagnostic

Summary

The purpose of this study is to determine the pharmacokinetics, dosimetry, tolerance, tumor detection rate of 68Ga-PSMA-33 in patient with Prostate Cancer (PCa).

Timeline

Start
2022-10-01
Primary completion
2023-10-01
Completion
2024-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject VIPIVOTIDE TETRAXETAN GALLIUM Diagnostic / imaging agent 111 mbq Intravenous
Subject VIPIVOTIDE TETRAXETAN GALLIUM Diagnostic / imaging agent 111 mbq —
Subject VIPIVOTIDE TETRAXETAN GALLIUM Diagnostic / imaging agent 259 mbq Intravenous
Subject VIPIVOTIDE TETRAXETAN GALLIUM Diagnostic / imaging agent 259 mbq —

Indications

prostate cancer